The last decade has been somewhat of a renaissance period for the field of macrophage
biology. This renewed interest, combined with the advent of new technologies and …

The fibrotic process could be easily defined as a pathological excess of extracellular matrix
deposition, leading to disruption of tissue architecture and eventually loss of function; …

Sphingosine kinase 1 (SphK1) a key enzyme that catalyzes the conversion of sphingosine
(Sph) to sphingosine 1-phosphate (S1P), so as to maintain the dynamic balance of …

Alveolar epithelial cell (AEC) mitochondrial (mt) DNA damage and fibrotic monocyte-derived
alveolar macrophages (Mo-AMs) are implicated in the pathobiology of pulmonary fibrosis …

PF-543 is a sphingosine kinase 1 (SPHK1) inhibitor developed by Pfizer and is currently
considered the most potent selective SPHK1 inhibitor. SPHK1 catalyses the production of …

Premature infants are born with developing lungs burdened by surfactant deficiency and a
dearth of antioxidant defense systems. Survival rate of such infants has significantly …

Mitochondrial dysfunction contributes to the imbalance of cellular homeostasis and the
development of diseases, which is regulated by mitochondria‐associated factors. The …

Bronchopulmonary Dysplasia is the most common long-term respiratory morbidity of preterm
infants, with the risk of development proportional to the degree of prematurity. While its …

Lymphangioleiomyomatosis (LAM), a progressive pulmonary disease exclusively affecting
females, is caused by defects or mutations in the coding gene tuberous sclerosis complex 1 …

Introduction Neonatal lung injury as a consequence of hyperoxia (HO) therapy and ventilator
care contribute to the development of bronchopulmonary dysplasia (BPD). Increased …